IKZF1 and cancer: Sensitivity of the methylated BCAT1/IKZF1 blood test for recurrence was 75.0% in patients with stage II cancer at diagnosis (6/8), 70.6% of the stage III cancers (12/17), and 33.3% of the stage IV cancers (1/3).